Absci Corp Stock News

VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI's main drug candidate for IBD. However, ABS-201 for hair loss and ABS-301 for solid tumors offer additional sizeable TAMs if successful. ABSI's AI models and wet lab data seem quite promising for discovering further antibodies that could be highly differen...

Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-...

$20 Million Equity Investment from AMD Strengthens Absci's Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software $20 Million Equity Investment from AMD Strengthens Absci's Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software

Collaboration leverages Absci's leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications Collaboration leverages Absci's leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications

Absci Corporation (NASDAQ:ABSI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Srikripa Devarakonda – Truist Securities Brendan Smith - TD Cowen George Farmer – Scotiabank Vamil Di...

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration

VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D Day on Thursday, December 12th in New York City.